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Abstract
Background: Successful treatment of allograft infections by 
the temporary implantation of an antibiotic-loaded polymeth-
ylmethacrylate cement spacer depends on the diffusion of 
antibiotics out of the cement and inhibition of bacterial 
growth in the surrounding tissue. We investigated with an in 
vitro model how long antibiotics are released by the cement 
and if gentamicin-resistant coagulase-negative staphylococci 
(CNS) are inhibited by vancomycin mixed with the 
gentamicin-loaded cement. 
Materials and Methods: Four formulations of antibiotic-
loaded cement disks, i.e. gentamicin, tobramycin, 
vancomycin and tobramycin combined with vancomycin, 
respectively, were used to test the inhibition of eight isolates 
of Staphylococcus epidermidis and two reference strains of 
Staphylococcus aureus by an agar diffusion test on 
Mueller-Hinton (MH) agar similar to the routine laboratory 
disk diffusion method. Moreover, cement spacer cylinders 
loaded with gentamicin alone or combined with vancomycin 
were submerged in MH agar for weeks and the capacity to 
inhibit five different isolates of S. epidermidis was measured.
Results: The size of the inhibition zones around the 
antibiotic-loaded cement disks correlated with the minimal 
inhibitory concentration (MIC) of the antibiotics against the 
tested strains. All five strains of S. epidermidis were inhibited 
by vancomycin-loaded cement spacers for at least 30 days. 
However, two gentamicin-resistant S. epidermidis strains with 
MICs of 4 mg/l and 16 mg/l could not be inhibited longer 
than 3 days by the gentamicin-loaded cement spacer.
Conclusion: The in vitro data suggest that antibiotic-loaded 
cement spacers inhibit susceptible bacteria for 4–6 weeks. The 
addition of vancomycin to commercial aminoglycoside-loaded 
cements might be helpful in allograft infections in tumor 
patients to inhibit a broad range of bacteria including genta-
micin-resistant CNS very commonly found in such infections.
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Introduction
Buchholz and Engelbrecht [1] introduced the concept of 
antibiotic-loaded polymethylmetacrylate (PMMA) bone 
cement over 30 years ago. After successful prophylactic 
use of gentamicin-loaded cement with a reduced rate of in-
fected endoprosthesis, they treated deep infections of total 
hip replacements by revision arthroplasty that comprised, 
in one stage, excision of soft tissue, removal of implant and 
cement and replacement with an appropriate implant using 
antibiotic-loaded cement [2]. Staged revision of infected 
prosthesis by using temporary antibiotic-loaded cement 
spacers may be preferred [3]. Systemic antibiotic treatment 
of infected bone reconstructions in tumor patients may be 
compromised by devascularization. Bacteria colonize the 
surface of inert biomaterial and adjacent, damaged tissue 
cells [4]. Therefore, antibiotic-impregnated cement spacers 
should inhibit bacteria locally before they form a biofilm. 
However, it is not well defined how long an antibiotic-
loaded cement spacer should be left in place before the 
definitive reconstruction can take place. 
Aminoglycosides are widely used because of their 
broad-spectrum activity and thermal stability [5, 6]. The 
high prevalence of highly resistant coagulase-negative 
staphylococci (CNS) in infected reconstructions may justify 
the use of vancomycin in bone cement. The present study 
investigates the in vitro inhibition of clinical isolates of 
Staphylococcus epidermidis by bone cement loaded with 
single antibiotics, i.e. gentamicin, tobramycin and vancomy-
cin, and loaded with vancomycin combined with tobramy-
cin, respectively. In addition, we developed a simple method 
to measure the time of the inhibition of bacteria which com-
bines the standardized method of disk diffusion and some of 
the in vivo conditions of cement spacers. Our in vitro model 
should demonstrate in an easier way that the antibiotic- 
loaded bone cement can elute antibiotic over weeks.
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Materials and Methods
Eight isolates of S. epidermidis, isolated from patients with ortho-
pedic infections and two reference strains of Staphylococcus aureus
(ATCC 29213, susceptible to methicillin; ATCC 43300, resistant to 
methicillin) were included in our in vitro inhibition assay by anti-
biotic-loaded cement disks. Five of those isolates were used to in-
vestigate their inhibition over weeks by cylindrical antibiotic-loaded 
cement spacers.
The minimal inhibitory concentrations (MIC) of gentamicin, 
tobramycin and vancomycin for those bacteria were determined by 
Etest strips containing the corresponding antibiotic calibrated with 
MIC values covering a scale of 15 twofold dilutions (AB Biodisk, 
Solna, Sweden). In brief, staphylococcal colonies of an overnight 
culture on sheep blood agar were suspended in saline and adjusted 
to match a 0.5 McFarland turbidity standard, i.e. containing ap-
proximately 1 to 2 × 108 CFU/ml. A sterile cotton swab was dipped 
into the suspension and Mueller-Hinton (MH) agar plates were 
inoculated by streaking the swab over the entire agar surface before 
one Etest strip per plate was placed onto each agar. They were incu-
bated for 24 h at 35 °C without CO2 and MICs were read where the 
growth inhibition ellipse intersected the scale. Synergy testing was 
also performed by Etest as above according to the instructions of 
the manufacturer. However, a first Etest strip with gentamicin was 
placed onto the inoculated MH agar for only 1 h and removed again 
before a second Etest strip with vancomycin was put in exactly the 
same place as the first; this experiment was also performed in paral-
lel for each strain by placing first the Etest strip with vancomycin 
for 1 h followed by the Etest strip with gentamicin overnight. Plates 
were incubated as above but the read MIC is the MIC of the com-
bination of both, gentamicin and vancomycin.
For the in vitro inhibition assay by antibiotic-loaded 
cement disks, four antibiotic-loaded cement formulations were 
used: (1) Palacos commercially prepared with 500 mg gen-
tamicin per 40.8 g cement powder (Biomet-Merck, Warsaw, 
Indiana, USA) and (2) Simplex commercially prepared with 1 g 
tobramycin (Stryker Howmedica Osteonics, Limerick, Ireland); 
two other formulations were prepared by hand-mixing 3.0 g of 
vancomycin hydrochloride (Vancocin, Lilly, Indianapolis, In-
diana, USA) with a tongue depressor into standard 40 g doses 
(3) of the standard Simplex P without antibiotic (Stryker How-
medica Osteonics, Limerick, Ireland) and (4) of the Simplex 
bone cement with tobramycin (Stryker Howmedica Osteonics, 
Limerick, Ireland). Single doses of each bone cement formula-
tion were vacuum mixed according to manufacturer’s instructions 
using a commercial cement mixer and delivery system (How-
medica Inc., Limerick, Ireland). Immediately after mixing, the 
cement was delivered into aluminum molds with cavities to 
produce uniform disk-shaped specimens with a diameter of 14 mm 
and thickness of 2 mm. Cured samples were inspected and any 
disks possessing gross voids or surface defects were discarded. The 
antibiotic-impregnated cement disks were used on the very same 
day of their production.
Suspensions of the eight isolates of CNS as well as of the two 
reference strains of S. aureus were prepared and streaked onto 
MH agar plates as above. After a few minutes the disks of antibi-
otic-loaded cement were placed into the middle of the inoculated 
MH agar plates and pressed down to ensure complete contact with 
the agar surface. Each strain was tested in duplicate with each 
cement disk formulation. Plates were incubated for 24 h at 35 °C 
without CO2. After 24 h the inhibition zones were measured.
Five of the eight isolates of S. epidermidis were included in 
the inhibition experiment with cylindrical antibiotic-loaded ce-
ment spacers. Two antibiotic-loaded cement formulations were 
used to prepare five of each cylindrical cement spacers: (1) Pala-
cos R-40 (40.8 g powder) commercially prepared with 500 mg 
gentamicin (Biomet-Merck) and (2) a formulation prepared by 
hand-mixing 3 g of vancomycin hydrochloride into the standard 
40 g doses of Palacos bone cement with 500 mg gentamicin 
(Biomet-Merck). Briefly, the Palacos R-40 with gentamicin was 
mixed with the entire contents of two ampoules of 18.8 g liquid 
component twice as much as normal in a bowl for 50 s with a 
sterile plastic spatula until a homogeneous fluid cement mixture was 
formed. The mixture was filled into a perfusor syringe OPS® 50 ml 
(Braun, Melsungen, Germany) and packed by the gum stamp of the 
syringe. The syringes were placed with the outflow part upside 
until the hardened spacers could be taken out of the syringes after 
10 min; they were stored at room temperature for 24 h. Further 
five cylindrical cement spacers were produced in the same way but 
3 g vancomycin was added to the solution into the mixing bowl. 
The cylindrical spacers had approximately the diameter of the 
spacers used in the tumor patients with allograft infections.
The cylindrical spacers were placed in the middle of cylindri-
cal glasses (Duran®, Schott, Mainz, Germany) containing 440 ml 
of liquid (50 °C) sterile MH agar so that 2–3 cm of the spacer were 
still above the level of the agar surface. After the agar became 
solid at room temperature, suspensions of staphylococci were 
prepared as above and streaked with a swab tightly over the entire 
agar surface around the cylindrical cement spacer. The cylindri-
cal glasses with the spacer in the agar were incubated at 37 °C 
without CO2 and diameters of inhibition were measured after 
24 h and incubation continued for some days (Figure 1). The cylin-
drical spacers that showed an inhibition of the staphylococci were 
then transferred to a new cylindrical glass with liquid (50 °C) 
sterile MH agar but the amount of agar was diminished by 
Figure 1. Cement spacer in a cylindrical glass with a zone of 
inhibition of the added staphylococci.
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20 ml (Figure 2a, b) so that the contact of the agar with the spacer 
cement not yet submerged in the former experiment can be ex-
cluded; otherwise, the contact of agar with the cement not sub-
merged in the earlier experiments would allow diffusion of antibi-
otics of the upper part of the spacer. Suspensions from overnight 
grown colonies from the same bacteria were streaked onto the 
agar and the inhibition zone was measured again after 24 h. At 
the beginning the intervals were short to detect an early loss of 
release of antibiotics by bone cement; the volume of the agar had 
to be reduced for each new transfer by 20 ml to be sure that the 
contact zone of the agar was not at a level of the cement spacer not 
yet submerged before; therefore, the interval was prolonged so 
that we could perform the experiment over 2 months. The experi-
ment was stopped earlier for those spacers that did 
not show any more inhibition zones or which were 
contaminated by molds.
Statistics
The MICs of the combination of gentamicin 
plus vancomycin or vancomycin plus gentami-
cin (Table 1) were compared with the MICs of 
the single compound with the lower MIC by the 
Wilcoxon signed-rank test to detect synergy, i.e. 
lower MICs of the combination than the MICs 
of the single compounds. The mean values of the 
duplicate zones of inhibition of the cement disks 
with vancomycin combined with tobramycin 
(Table 2) were compared with the mean values 
of the single compound with the bigger zone 
by the Wilcoxon signed-rank test to detect 
synergy, i.e. greater inhibition zones of the disks 
with combined antibiotics.
Results
The MICs of the eight strains of S. epidermi-
dis and of the two reference strains of S. au-
reus are shown in table 1. The MICs of the syn-
ergy testing by Etest were not different from 
the MICs of the single component which was 
most active against the corresponding strain 
(p = 0.38 for the gentamicin plus vancomycin 
combination, p = 0.69 for the vancomycin plus 
gentamicin combination). Inhibition zones of 
the antibiotic-loaded cement disks were mea-
sured after an overnight incubation (Table 2). 
The duplicate values did not differ more than 
2 mm with the following exception: the in-
hibition zones of the two cement disks with 
vancomycin combined with tobramycin were 
30 mm and 37 mm for strain V10 21204. The 
diameters of the zones around the cement disks 
loaded with vancomycin and tobramycin were 
not different from those of the most active sin-
gle antibiotic (p = 0.96). Furthermore, the zones 
were greater for strains with low MICs than for strains with 
higher MICs and strains with MICs greater than 12 mg/l 
did not show any inhibition zone with the corresponding 
cement disks.
The zones of inhibition of the ten cement spacers are 
shown in table 3. Only one of the spacers loaded with gen-
tamicin alone (V10 22259) showed a zone of inhibition un-
til the 8th week. The two spacers incubated with strains 
with elevated MICs against gentamicin (V01 17734 and 
V10 21204, see Table 2) stopped showing a zone of inhibi-
tion after 2 and 3 days. The corresponding spacers loaded 
with gentamicin and vancomycin inhibited the same strains 
of S. epidermidis over 7 weeks. The zones of inhibition of 
Figure 2. a) Cement spacer in the cylindrical glass at the beginning of the 
experiments; b) Cement spacer in the cylindrical glass 5 weeks later.
Table 1
Minimal inhibitory concentrations (MIC) of all isolates determined by Etest.
Organism MIC in mg/l
Tobramycin Vanco-
mycin
Gentamicin 
plus 
vancomycin
Vancomycin 
plus 
gentamicin
Genta-
micin
Staphylococcus aureus 
ATCC 43300 > 256 1.5 0.75 0.38 32
ATCC 29213 1.0 1.0 1.0 1.0 0.38
Staphylococcus epidermidis
V07 33499 0.38 2 0.19 0.125 0.125
V10 33001 2 2 0.25 0.125 0.125
V10 22259 8–12 1.0 0.38 0.19 0.25
V01 17734 > 256 1.5 2 2 16
V07 21204 > 256 2 1.5 1.5 4
V01 15748 > 256 2 2 2 4
V10 28533 > 256 2 0.25 0.19 0.19
V09 15128 > 256 2 2 2 > 256
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the other two gentamicin-loaded spacers were only mea-
surable for 3 and 8 days, respectively, because they were 
contaminated by environmental strains.
Three of five spacers loaded with gentamicin and van-
comycin (V07 33499, V10 22259, V10 21204) still showed a 
zone of inhibition at the end of the study after more than 
15 diffusion experiments; spacer V10 22259 showed a tran-
sient contamination by fungus. Two spacers (V01 17734, 
V07 28533) produced after 7 and 4 weeks, respectively, 
irregular zones and were not transferred for further experi-
ments.
Discussion
It is known that many commonly used antibiotics are 
released from bone cement in such a way that the local 
antibiotic levels vastly exceed the MICs needed for 
treating most susceptible pathogens, and that the lev-
els are much higher than those achieved with par-
enteral therapy [7]. When used in PMMA, the 
antibiotic agent must be heat stable and effective against 
the common pathogens and exhibit good elution char-
acteristics [8]. Previous studies measured in vitro the 
released antibiotics in fluids surrounding antibiotic-loaded 
cement [9–11] or in vivo in wound drainage, urine and 
serum [12–14].
The time period of antibiotic release out of the bone 
cement reached days to several months in earlier stud-
ies and the diffusion is influenced by the cement-, antibi-
otic- and environment-dependent factors [15]. The elu-
tion characteristics of different bone cements depend on 
handling, physical states and physical characteristics, i.e. 
speed of creep and relaxation [16]. Some authors reported 
that Palacos releases more gentamicin and vancomycin [12, 
14, 17–20] and has more rapid elution characteristics than 
Simplex-P, which is probably due to its greater porosity 
than other cements [7, 21]. In contrast, Simplex-P bone 
cement has superior handling characteristics [7]. Other 
studies claimed that the elution capacity of CMV (DePuy 
International, Blackpool, UK) may be greater than that of 
Palacos R [20, 22].
Our freshly prepared antibiotic-loaded cement disks 
released tobramycin, gentamicin and vancomycin into the 
agar, as shown in previous studies [8, 19, 23]. The con-
centration of antibiotics is highest near the disk and the 
bacterium is inhibited if the MIC is lower than this con-
centration. The staphylococci were only inhibited by the 
aminoglycoside-loaded cement disks if the correspond-
ing MIC in the Etest was lower than 16. The concentra-
tion of the antibiotic at the edge of the inhibition zone 
corresponds to the MIC of the bacterium and the inhi-
bition zones correlated – with one exception – with the 
MIC of the corresponding staphylococci, i.e. the lower 
the MIC the bigger was the inhibition zone. The addition 
of vancomycin to tobramycin resulted in an inhibition of 
all staphylococci including those six strains against which 
MICs of tobramycin were > 256. However, the inhibition 
zones of tobramycin combined with vancomycin were 
not significantly greater for the other staphylococci than 
those of the more potent antibiotic alone. This was also 
observed by Etest where the combination of gentamicin 
with vancomycin revealed MIC similar to the MIC of the 
most active antibiotic. We could not observe a synergistic 
inhibition of tobramycin or gentamicin with vancomycin 
in vitro. However, we did not measure the bactericidal 
effect of the combination of vancomycin and gentamicin. 
A bactericidal synergy of two substances that interact 
with different targets of the bacteria might be helpful to 
eliminate the bacteria from the bone similar to synergis-
tic action of vancomycin or penicillin with gentamicin in 
enterococcal endocarditis [24]. Furthermore, aminoglyco-
sides alone might promote the formation of small colony 
variants of staphylococci [25, 26]. Small colony variants 
of staphylococci have been recovered from patients with 
unusually persistent infections which are chronically ex-
posed to aminoglycosides. The addition of vancomycin 
might prevent the formation of small colony variants but 
this has to be studied further. The reason for the addition 
of vancomycin is, however, to inhibit those staphylococci 
that are not inhibited by the eluted amounts of aminogly-
cosides out of the cement.
Our experiments with cement spacers show that 
enough antibiotic was eluted into the agar to inhibit bac-
teria. However, the two strains of S. epidermidis with MIC 
4 and 16 against gentamicin were not inhibited after 3 days. 
The spacers with vancomycin released antibiotics until the 
end of the experiment over 8 weeks. This is in contrast 
with previous reports that vancomycin is not well eluted 
from antibiotic-impregnated bone cement in total hip ar-
throplasty [13].
Table 2
Zones of inhibition of the antibiotic-loaded cement disks with the 
agar diffusion method
Organism Zone of inhibition of duplicate
cement disks (first, second disk) in mm
Tobramycin Vanco-
mycin
Vancomycin 
plus 
tobramycin
Genta-
micin
Staphylococcus aureus 
ATCC 43300
(MRSA)
No zone 27, 28 26, 27 No zone
ATCC 29213 30, 30 28, 28 32, 32 31, 31
Staphylococcus epidermidis
V07 33499 35, 36 28, 28 38, 39 38, 37
V12 33001 26, 26 30, 29 29, 28 36, 37
V10 22259 23, 24 28, 30 29, 28 34, 33
V01 17734 No zone 31, 31 30, 28 No zone
V10 21204 No zone 30, 31 30, 37 24, 23
V01 15748 No zone 34, 33 34, 32 26, 26
V07 28533 No zone 31, 32 31, 32 40, 40
V09 15128 No zone 28, 28 26, 28 No zone
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However, the addition of vancomy-
cin might be a microbial ecological risk 
[27]. Gradual development of vancomycin 
resistance could occur as a result of wide 
use of vancomycin with prolonged release 
in subtherapeutic doses or the employ-
ment of large amounts. Therefore, vanco-
mycin-loaded cement is suggested only for 
revisions of infected arthroplastic and for 
high-risk procedures. Failure of infection 
control in massive tumor reconstruction may 
result in the loss of the extremity. Since most 
CNS of orthopedic infections are resistant to 
gentamicin, vancomycin might inhibit those 
bacteria. Aminoglycosides are particularly 
effective against gram-negative bacteria, 
and cannot be replaced totally by vanco-
mycin.
We conclude that these in vitro experi-
ments support reasonable use of vancomy-
cin loaded spacers in tumour patients with 
infected reconstructions by CNS. Although 
we observed antibiotic elution over 8 weeks 
we suggest that the spacer should be changed 
every 4–6 weeks since the declining antibi-
otic concentration may no longer inhibit the 
CNS, the most prevalent infectious patho-
gens in infected allografts. These data have 
to be confirmed by in vivo experiments; we 
recently started to investigate explanted 
cement spacer from patients to detect their 
inhibition of CNS.
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